All News

GSK and Merck won high marks from physicians for their electronic promotions, according to a new study. But do docs really want to skip the live sales calls and go online for info?

GSK, Pfizer, and Merck have jumped on the cell-phone marketing bandwagon, but most of pharma is still tiptoeing around the technology. A new report details how pharma can get consumers to text for health info.

With M&As the new R&D and sales forces getting axed, the CFO is transitioning from background player to front man. A new survey documents the changing role of the pharma controller.

While some drugmakers are being pummeled for data on their "bad" cholesterol?lowering drugs, promising Phase II stats about its "good" cholesterol?raising CETP inhibitor has Roche smiling. Can it escape the torcetrapib curse?

California's plan for full-blown ePedigree implementation by 2009 just got a reality check. The hang-up? The systems are cost more and are taking longer than expected to get up and running.

Veteran salesperson Reggie Smith of Genentech makes the case for sales force diversity

Pharma is embracing the cross-functional team. But that doesn't mean that you must blend in with the sheep. Putting your best foot forward strengthens the team...and you.

Promotions and accolades form for Community section of Pharmaceutical Representative.

International outsourcing carries risks for marketers and regulatory challenges for FDA

The real question in the Baxter heparin scandal is not who's guilty but whether pharma can get reliable results from a country in chaos

When it comes to developing novel therapies from the animal kingdom, it's mostly a game of pick your poison

The real question in the Baxter heparin scandal is not who's guilty but whether pharma can get reliable results from a country in chaos

A new study looks at the movement of thought leaders and medical science liaisons from primarily marketing to other areas of the pharma company. Though the shift might be minor (7 percent since 2002), it might be a sign of things to come.

Now that Apple has opened its iPhone to third-party software developers, healthcare productivity programs are leading the charge. Here?s a preview of one of the frontrunners.

What will the next president really mean for US healthcare policy? PwC's Sandy Lutz reports.

The US pharma market grew just 3.8 percent last year, according to IMS Health. The big loser: lipid regulators. The winners: Biologic response modulators and monoclonal antibodies.

Pharma is still having a hard time earning the confidence of the key opinion elite, as only 56 percent claim they trust the industry.

Johnson & Johnson's biologics division launches a new blog in an effort to release easy-to-digest health information and corporate news.

A Kaiser Foundation study finds that although most Americans look favorably upon pharmaceuticals, they generally think drugs are too expensive and that most of the cost is blown on advertising.

PACME final brochure

PACME brochure

A review of a pilot ePrescribing program reveals that if physicians are given the proper support, the technology can increase safer prescribing habits and boost compliance.

"!-- -->

Congress is firing plenty of ammunition at pharma companies-and the regulators

For pharma to function, it needs a whole network that commands trust. The only alternative is the sort of regulation by mass tort that we've been sliding into in recent years